{"id":15003,"date":"2026-06-03T01:30:00","date_gmt":"2026-06-02T23:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=3371e0d45339a79c3b2ab1fb0c5e0958"},"modified":"2026-06-03T01:30:00","modified_gmt":"2026-06-02T23:30:00","slug":"agenus-announces-virtual-2026-annual-shareholders-meeting","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=15003","title":{"rendered":"Agenus Announces Virtual 2026 Annual Shareholders Meeting"},"content":{"rendered":"

LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN<\/a> #AGEN<\/a>--Agenus Inc.<\/a> (\u201cAgenus\u201d) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET.<\/p><\/a><\/a>

\nTo participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com\/AGEN2026<\/a> and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.<\/p>

\nWebcast Information:<\/b><\/p>

\nDate<\/b>: Tuesday, June 16, 2026<\/p>

\nTime<\/b>: 10:00 a.m. ET<\/p>

\nA live webcast and replay will be accessible on the Company\u2019s website at https:\/\/investor.agenusbio.com\/events-and-presentations<\/a> and at www.virtualshareholdermeeting.com\/AGEN2026<\/a>.<\/p>

\nVoting Information:<\/b><\/p>

\nShareholders of Agenus as of the April 22, 2026, record date can vote. Alliance Advisors, Agenus\u2019s proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@AllianceAdvisors.com<\/a>.<\/p>

\nAbout Agenus<\/b><\/p>

\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.<\/p> Contacts<\/b>

\nInvestors<\/b>917-362-1370 | investor@agenusbio.com<\/a><\/p>

\nMedia<\/b>781-674-4422 | communications@agenusbio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #AGEN–Agenus Inc. (\u201cAgenus\u201d) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15003","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15003"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15003\/revisions"}],"predecessor-version":[{"id":15004,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15003\/revisions\/15004"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}